Stay updated with breaking news from Major Symposium. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
02.05.2024 - KT-474/SAR444656 (IRAK4) Phase 2 clinical trials ongoing in HS and AD with data expected in the first half of 2025 KT-621 (STAT6) expected to start Phase 1 in the second half of 2024 and KT-294 (TYK2) expected to start Phase 1 in the first half of ...
Targeted therapy, genomics, and treatment disparities were among the topics that were presented by researchers from UCSF at the 2024 AACR conference.
Presented new case studies demonstrating clinical responses in two patients with B cell malignancies, chronic lymphocytic leukemia (CLL) and primary...
Nurix Therapeutics, Inc. announced the presentation of the first findings of clinical responses in the brain for NX-5948, an orally available, selective degrader of Bruton's tyrosine kinase . The...
New preclinical data on novel E3 pairing and structural mechanisms for KT-333, a First-in-Class STAT3 degrader, presented in AACR’s late-breaking poster session Nello Mainolfi, Founder, President and CEO of Kymera, invited as a featured speaker in AACR’s Major Symposium to discuss drug discovery and clinical translation strategies for STAT3 and MDM2 degrader programs KT-333 and KT-253 Phase 1 dose escalation studies ongoing with additional data expected in 2024 WATERTOWN, Mass., April 08, 2024 (